Investigating how a specific protein interacts with others in kidney disease
Apolipoprotein L1 Interaction with SNARE Proteins in the Pathogenesis of Chronic Kidney Disease
This study is looking at how a protein called APOL1 might affect kidney health, especially in African Americans who are more likely to develop chronic kidney disease, to help find new ways to prevent or treat this condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10830348 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called Apolipoprotein L1 (APOL1) in the development of chronic kidney disease (CKD), particularly in African American populations who are at higher risk. The study aims to explore how genetic variants of APOL1 affect its interaction with other proteins involved in cellular processes within kidney cells. By using advanced techniques like live-cell microscopy and stable cell lines, researchers will identify how these interactions may contribute to kidney damage and disease progression. This could lead to new insights into the mechanisms of CKD and potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals of African ancestry who are at risk for or currently experiencing chronic kidney disease.
Not a fit: Patients without a genetic predisposition to chronic kidney disease or those with kidney disease unrelated to APOL1 variants may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for chronic kidney disease, particularly for those at higher genetic risk.
How similar studies have performed: Previous research has shown that understanding protein interactions in cellular processes can lead to significant advancements in treating various diseases, suggesting potential success for this approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Madhavan, Sethu Madhavan — Ohio State University
- Study coordinator: Madhavan, Sethu Madhavan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.